Qing Xu

Qing Xu

Auto-generated profile, based on publicly available information

Qing Xu

School of Pharmacy, Guilin Medical University, Guilin541199, P.R. China

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2012 in Cancer Cell
Verified
Journal Article
Closed access
MMMichael A. Milhollen
Michael A. Milhollen
MTMichael P. Thomas
Michael P. Thomas
UNUsha Narayanan
Usha Narayanan
TTTary Traore
Tary Traore
JRJessica Riceberg
Jessica Riceberg
PSPeter Smith
Peter Smith

16 February 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
JWJingchen Wei
Jingchen Wei
YLYunfei Lu
Yunfei Lu
YRYing Rui
Ying Rui
XZXuanyu Zhu
Xuanyu Zhu
SHSongqing He
Songqing He
QXQing Xu
Qing Xu
COVID-19 pneumonia has now spread widely in the world. Currently, no specific antiviral drugs are available. The vaccine is the most effective way to control the epidemic. Passive immune antibodies are also an effective method to prevent and cure COVID-19 pneumonia. We used the SARS-CoV-2 S receptor-binding domain (RBD) as an antigen to immunize layers in order to extract, separate, and purify SARS-CoV-2-IgY from egg yolk. SARS-CoV-2-IgY (S-IgY)can block the entry of SARS-CoV-2 into the Cells and reduce the viral load in cells. The Half effective concentration (EC 50 ) of W3-IgY (S-IgY in the third week after immunization) is 1.35 ± 0.15nM. The EC 50 of W9-IgY (S-IgY in the ninth week after immunization) is 2.76 ± 1.54 nM. When the dose of S-IgY is 55 nM, the fluorescence representing intracellular viral protein is obviously weakened in Immunofluorescence microscopy. Results of Sars-CoV-2 /Vero E6 cell experiment confirmed that S-IgY has a strong antiviral effect on SARS-CoV-2, and its (EC 50 ) is 27.78 ±1.54 nM vs 3,259 ± 159.62 nM of Redesivir (differ > 106 times P<0 . 001 ). S-IgY can inhibit the entry and replication of SARS-CoV-2, which is related to its targeting the ACE2 binding domain. S-IgY is safe, efficient, stable, and easy to obtain. This antibody can be an effective tool for preventing and treating COVID-19 pneumonia. Abstract Figure: Fig. 1. Graphical The figure briefly illustrates that the preparation and extraction of S-IgY and its anti-S-CoV-2 mechanism is to inhibit the entry and replication of SARS-CoV-2 by targeting the ACE2.